The USTR has announced that it is further extending certain China 301 exclusions that had been put in place and/or previously extended to help address the COVID-19 pandemic. The 81 exclusions at issue, which had been extended through May 31, 2022, are now being further extended through November 30, 2022. The extensions are effective for […]
COVID-19
USTR EXTENDS EXPIRING CHINA 301 TARIFF EXCLUSIONS ON CERTAIN MEDICAL CARE PRODUCTS THROUGH NOVEMBER 14, 2021
The Office of the United States Trade Representative (“USTR”) announced that it is temporarily extending the China 301 tariff exclusions on 99 medical care products through November 14, 2021. On December 29, 2020, in response to the evolving COVID-19 situation, the USTR had announced that it was extending expiring China 301 tariff exclusions on certain […]
USTR SEEKS COMMENTS ON THE EXTENSION OF CHINA 301 TARIFF EXCLUSIONS ON CERTAIN MEDICAL CARE PRODUCTS
In a Federal Register Notice of August 27, 2021, the Office of the U.S. Trade Representative (“USTR”) announced that it is seeking comments on the extension of existing China 301 exclusions on certain medical care products. On December 29, 2020, in response to the evolving COVID-19 situation, the USTR had announced that it was extending […]
USTR EXTENDS CERTAIN CHINA 301 EXCLUSIONS COVERING CERTAIN MEDICAL-CARE PRODUCTS THROUGH SEPTEMBER 30, 2021
In a notice recently posted on its website, the Office of the U.S. Trade Representative (“USTR”) has announced that it is extending 99 expiring China 301 tariff exclusions on medical-care and/or COVID response products. The exclusions on the products in question had been previously extended through March 31, 2021. The USTR has decided to further […]
USTR EXTENDS CERTAIN CHINA 301 EXCLUSIONS AND DESIGNATES ADDITIONAL EXCLUSIONS FOR THE PERIOD JANUARY 1 – MARCH 31, 2021
The Office of the U.S. Trade Representative (“USTR”) has announced that it is extending certain expiring China 301 tariff exclusions and is designating certain additional such exclusions. The USTR is taking these actions with respect to certain medical-care products to reflect the rising spread and ongoing efforts to combat COVID-19. (Notice accessible at: https://ustr.gov/sites/default/files/enforcement/301Investigations/COVID_Extensions_December_2020.pdf). In […]
UPDATE: USTR ANNOUNCES THE MODIFICATION OF A 301 LIST 1 PRODUCT
On June 5, 2020, the U.S. Trade Representative (“USTR”) announced the modification of a China 301 List 1 exclusion as described below: Original Language Amended Language Machines for crushing/grinding pills, each valued over $20 but not over $35 (described in statistical reporting number 8479.82.0080) Machines for crushing/grinding pills, each valued not over $35 (described in […]
UPDATE: USTR ANNOUNCES ADDITIONAL EXCLUSIONS GRANTED ON SEC. 301 LIST 3 PRODUCTS
On April 23, 2020, the U.S. Trade Representative (“USTR”) announced that 108 items will be excluded from the Section 301 trade remedies imposed on Chinese-origin products. The newly announced exclusions all relate to items on China 301 List 3 (which is part of the $200 billion trade action) which, unless excluded, are currently subject to […]
USTR SOLICITING COMMENTS ON THE REMOVAL OF CHINA SEC. 301 DUTIES FROM ADDITIONAL MEDICAL-CARE PRODUCTS
In a March 23, 2020 notice, the Office of the United States Trade Representative (“USTR”) has solicited comments identifying additional medical-care items that should be excluded from China Section 301 tariffs in light of the ongoing COVID-19 outbreak. The comment period will remain open at least until June 25, 2020 (subject to potential extensions as […]